Mineralys Therapeutics, Inc.

MLYS

$25.39

Updated: 25/09/2026, 16:47:11

Market Cap

$2.24B

Sector

Healthcare

Industry

Biotechnology

Country

Stock valuation chart

One-year closing share-price history for MLYS

Company Profile

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.

USD

NASDAQ

CEO: Jon Congleton

Employees: 76

https://mineralystx.com

Asset Summaries

Latest generated summaries for MLYS

No summaries found.

Detailed business

Structured knowledge from the latest official annual filing.

No official annual filing has completed ingestion for this company yet. The filing worker processes major-index companies incrementally and never repeats a completed fiscal year.

Full company information

Latest profile, trading, valuation, and identifier data stored for MLYS.

Share price: $25.39
Market cap: $2.24B
Exchange: NASDAQ
Currency: USD
CEO: Jon Congleton
Employees: 76
IPO date: 10/02/2023
Beta: 0.675
Last dividend: $0.00
Day range: $25.36 – $26.55
52-week range: $22.30 – $47.65
1-day performance: -4.53%
1-year performance: 13.83%
Current drawdown (1Y): -46.73%
CIK: 0001933414
CUSIP: 603170101
ISIN: US6031701013
Created: 07/12/2025, 05:16:38
Last update: 25/09/2026, 16:47:11

Track Mineralys Therapeutics, Inc. with an AI analyst

See which prediction-market events move MLYS, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.

Create a free account See what the world decides next

Free forever to follow AlphaBrain’s AI strategies. No card required.

Latest Database News

News linked to MLYS from your Railway `news_articles` table.

Mineralys Therapeutics, Inc. (MLYS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Seeking Alpha • STOCK • 11/06/2026, 05:22:10

Mineralys Therapeutics Announces Repurchase of Royalty Obligations in Tanabe License Agreement and Concurrent Financing

GlobeNewsWire • STOCK • 03/06/2026, 08:00:00

Mineralys' pill cuts blood pressure in kidney disease patients

Reuters • STOCK • 30/05/2026, 13:20:04

Mineralys Therapeutics Presents New Data from the Phase 3 Launch-HTN Trial of Lorundrostat in Participants with Hypertension and Chronic Kidney Disease at European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)

GlobeNewsWire • STOCK • 30/05/2026, 13:15:00

Mineralys Therapeutics, Inc. (MLYS) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Seeking Alpha • STOCK • 12/05/2026, 18:30:49

Mineralys Therapeutics, Inc. (MLYS) Q1 2026 Earnings Call Transcript

Seeking Alpha • STOCK • 07/05/2026, 05:41:30

Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference

GlobeNewsWire • STOCK • 05/05/2026, 10:00:00

Mineralys Therapeutics Appoints Jeffrey A. Munsie as Chief Legal Officer

GlobeNewsWire • STOCK • 24/03/2026, 09:00:00

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Overview and Financial Insights

Market Data • Market Data • 13/03/2026, 21:05:57

Mineralys Therapeutics, Inc. (MLYS) Q4 2025 Earnings Call Transcript

Seeking Alpha • STOCK • 12/03/2026, 20:32:17

Mineralys Stock Rises as FDA Accepts NDA for Hypertension Drug

Zacks Investment Research • STOCK • 11/03/2026, 13:35:32